Peptides in Sports: The Grey Zone Between Healing and Cheating

Where healing meets the rulebook

Most athletes who look into peptides aren't chasing size. They have a tendon that won't settle or a muscle tear that keeps flaring, and they read that BPC-157 or TB-500 speeds tissue repair. Nearly all of that evidence comes from animals: a 2025 systematic review in HSS Journal found 35 preclinical studies of BPC-157, one small human case series, and no clinical safety data.

For a tested athlete, the reason for use doesn't change the rule. As of October 2026, WADA's 2026 Prohibited List bans BPC-157 by name under S0 (non-approved substances) and TB-500 by name under S2.3 (growth factors), both at all times. S2.3 covers growth factor modulators "affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching." On the list's own terms, faster tissue repair counts as an advantage.

That is the core disagreement. One side argues that restoring normal function isn't cheating. The other argues that recovery speed is performance: an athlete who heals in four weeks instead of eight trains and competes more, and a "healing-only" exception would be close to impossible to police.

How a substance ends up on the list

Under the World Anti-Doping Code (the 2021 version, which stays in force until the 2027 Code takes effect on January 1, 2027), WADA can list a substance that meets any two of three criteria: it enhances or could enhance performance, it poses an actual or potential health risk, or it violates the "spirit of sport." So an unapproved compound with no human safety data can qualify without any proven performance effect. The Code also makes WADA's classification decisions final: an athlete can't defend a case by arguing that a listed substance doesn't enhance performance, so the "it only heals" argument carries no weight in a hearing.

S0 is narrower than it's often described. It catches a substance only if no later section of the list covers it and no government health authority has approved it for human use. Approval alone doesn't make a peptide permitted, though. Tesamorelin is an FDA-approved prescription medicine (Egrifta) for abdominal fat in HIV-associated lipodystrophy, and it is still banned under S2.2.4 as a GHRH analogue.

Where common peptides sit (as of October 2026)

"Specified" doesn't mean less serious; WADA says these substances are simply more likely to have been used for reasons other than performance. The defaults come from Code Article 10.2 and can be reduced for low fault or early admission.

The 2027 list, in force from January 1, 2027, keeps these placements. According to USADA's 2027 advisory, it also adds "peptides" in general to the S0 examples, and a peptide not named on the list may still be prohibited.

Real cases: a prescription or a clean test doesn't settle it

USADA's published decisions show how these rules play out.

• Cortney Casey (MMA, 2023). Casey self-reported using BPC-157 that a doctor had prescribed and provided for a medical condition. She received a four-month suspension, reduced for her prompt disclosure and cooperation. USADA's announcement states that a TUE "was not applicable to this Non-Approved Substance."
• Kamryn Lute (speedskating, 2024). An arbitrator gave Lute, 19, a one-year ban for a supplement containing BPC-157 that a medical provider recommended. She never tested positive; her own declaration and admission were the evidence.
• Anthony McCauley (triathlon, 2025). After a whistleblower tip, USADA found that McCauley possessed and used BPC-157 and TB-500. He had also promoted several prohibited peptides on social media to followers who included Code-bound athletes, which USADA treated as attempted complicity. He accepted a four-year ban.

A positive test isn't required: admissions, documents and witness evidence can be enough. And under the Code's strict liability rule, athletes are responsible for what enters their bodies no matter who recommended it. Urine testing works as well: the HSS Journal review summarizes analytical studies that detected BPC-157 metabolites in urine for about 4-5 days.

Why a TUE rarely helps

A therapeutic use exemption (TUE) lets an athlete use a prohibited substance for a diagnosed condition. WADA requires all four of these conditions:

1. A diagnosed medical condition supported by relevant clinical evidence.
2. The substance is an indicated treatment, with no reasonable permitted alternative.
3. Use won't enhance performance beyond a return to the athlete's normal state of health.
4. The need isn't a consequence of earlier prohibited use without a TUE.

In our reading, an unapproved peptide fails the second condition almost by definition. BPC-157 and TB-500 have no approved indication and no human trial showing they treat any injury, and no human dose data a committee could use to judge the third condition. The Casey case shows USADA applying this, and the 2027 TUE standard keeps the same four conditions. Approved prescription medicines on the list, such as insulin for diabetes, are the cases TUEs are built for.

Critics call this a catch-22: an athlete whose injury might respond to an unapproved compound has no legal route to try it while competing. Defenders say the same gap protects athletes from pressure to self-experiment with untested drugs to keep their place on a team.

Informed consent without a trial

In a clinical trial, informed consent comes with a protocol, a characterized product and someone tracking adverse events. People using research-use-only peptides get none of that; their consent usually rests on forum posts and vendor pages. The gaps that matter most for athletes:

• What's in the vial. Gray-market peptides aren't made to drug standards. The HSS Journal review names unregulated manufacturing and contamination as plausible sources of harm, and cites estimates that 12-58% of sports supplements contain undeclared substances. For a tested athlete, that can mean a second prohibited substance they never meant to take.
• Long-term safety. None of the animal studies in that review followed adverse events past six weeks, and none assessed safety in humans. Our article on long-term effects of peptide use covers what is known across peptide classes.
• Unmeasured side effects. The review's authors note that online users describe injection-site pain, anxiety, insomnia, fatigue and low mood with BPC-157. These are user reports, but no trial has looked for them either.

Lab work can catch some problems early; our guide to baseline and on-cycle lab tests explains which markers people track, and blood work by peptide class differs. No blood test shows what a vial actually contains.

The people around the athlete

The Code covers more than athletes. Coaches, medical staff and others can be sanctioned for trafficking, administering a prohibited substance, or complicity. The HSS Journal review notes that licensed practitioners, including sports medicine specialists, offer BPC-157 injections despite the lack of human outcome data, and its authors recommend that clinicians ask athletes directly about peptides and counsel them on their sport's rules. Two of the three USADA cases above began with a provider's prescription or recommendation.

Untested lifters

Outside Code-governed sport, WADA's list doesn't apply. Some federations that aren't WADA signatories test under their own rules, so the relevant list is the one that federation publishes. Where nobody tests, the ethical questions shift from fairness toward honesty and risk. Lifters who use peptides while presenting themselves as natural, in a natural division or to an online audience, are making a claim others rely on. And a teenager copying an online protocol, who may later compete in tested sport, inherits the consequences.

What we still don't know

• Human evidence for the repair peptides. As of October 2026, no controlled human trial of BPC-157 or TB-500 for injury has published results. A randomized, placebo-controlled BPC-157 pilot in about 30 rotator cuff surgery patients (NCT07803250, University of Arkansas) is registered with a planned start in January 2027.
• Approved melanocortins and the list. The list doesn't name bremelanotide, and we found no WADA statement on how it's treated now that it's approved as Vyleesi. Its status for tested athletes is unverified.
• Sanctions under the 2027 Code. The ban lengths above come from the 2021 Code; the 2027 Code takes effect on January 1, 2027, and its sanction rules may differ in detail.
• Newer peptides. USADA notes that experimental peptides may be sold online, sometimes under slang names, before anti-doping labs know about them.